Company Focus
Vertex Pharmaceuticals
Latest Vertex Pharmaceuticals News
Pharmaceutical
Vertex Pharmaceuticals today announced that the European Commission has granted approval for Alyftrek (deutivacaftor/tezacaftor/vanzacaftor) for the treatment of people with cystic fibrosis (CF) ages six years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. 1 July 2025
Related News
Insights
Company Spotlight
UK drug discovery firm Summit Pharmaceuticals is an Oxford-based drug discovery and development company targeting high-value areas of unmet medical need including Duchenne Muscular Dystrophy and C. difficile infection.
Latest News & Features of interest to Vertex Pharmaceuticals
Pharmaceutical
Swedish biotech Camurus has secured EU marketing authorization for its once-monthly acromegaly therapy, Oczyesa (octreotide), marking a significant step forward in treatment convenience for patients living with the rare endocrine disorder. 1 July 2025
Biotechnology
Systemic sclerosis is an autoimmune connective tissue disease that causes debilitating fibrosis of the skin and internal organs. It impacts nearly 50,000 people in the USA alone1 and between 7.2 and 33.9 per 100,000 individuals across Europe.2 1 July 2025
Biotechnology
Australian biotech Dimerix today revealed it has received the first development milestone payment of 400 million yen (~AU$4.2 million; US$2.7 million) from Japan’ FUSO Pharmaceutical, the exclusive licensee of DMX-200 for the treatment of focal segmental glomerulosclerosis (FSGS) kidney disease in Japan. 30 June 2025
Pharmaceutical
US biotech major Amgen, a late comer to the growing obesity treatment space, released new data showing that its MariTide reduced weight by 20%. In deal-making news last week, US drugmaker Amarin struck a deal with Italy’s Recordati for the marketing of its cardiovascular drug Vazkepa in 59 countries, mostly Europe. Also, USA-based Vor Bio signed an exclusive agreement to acquire to RemeGen’s myasthenia drug telitacicept. Also of note, the US Centers for Disease Control and Prevention CDC) new advisory committee, the ACIP, met last week to review a number of vaccines. 29 June 2025
Biotechnology
North Carolina, USA-based biotech BioCryst Pharmaceuticals on Friday announced it has signed a definitive agreement to sell its European Orladeyo (berotralstat) business to Italy’s Neopharmed Gentili for up to $264 million. 28 June 2025
article
Swedish Orphan Biovitrum, the Nordic biotech also known as Sobi on Frida,y announced that the US Food and Drug Administration (FDA) approved Gamifant (emapalumab-lzsg) for a new indication, edging the company’s shares up 2.4% to 284.60 kronor. 28 June 2025
Pharmaceutical
US biotech Arbutus Biopharma has reacquired the rights to its lead hepatitis B candidate, imdusiran (AB-729), in China, ending a nearly four-year partnership with Qilu Pharmaceutical. 27 June 2025
Biotechnology
US biotech major Biogen today announced new data that reinforce the clinical impact of nusinersen across a broad spectrum of individuals affected by spinal muscular atrophy (SMA). 27 June 2025
Pharmaceutical
Belgian pharma UCB today announced that the Phase III study investigating the safety and efficacy of adjunctive fenfluramine in CDKL5 deficiency disorder (CDD) met its primary and key secondary endpoints. 27 June 2025
Pharmaceutical
US biopharma company Altimmune saw its share slump almost 55% to $3.48 yesterday, after it announced what it called ‘positive’ top-line results from the IMPACT Phase IIb trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH). 27 June 2025
Latest In Brief for Vertex Pharmaceuticals
Biosimilars
Hungarian drugmaker Gedeon Richter has announced that the European Commission has granted marketing authorization for the biosimilar denosumab products Junod and Yaxwer. 2 July 2025
Latest Relevant Ones To Watch News
US pharma giant Merck & Co today revealed it has made a bid to acquire UK-based lung therapy company Verona Pharma, sending the latter’s shares up 20.4% to $104.61 in pre-market activity. 13 July 2025
16 May 2025
30 April 2025
28 April 2025
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze